Apricus Biosciences Shareholder Notice: Dr. Irwin Goldstein Presents Phase III Trial Updated Preliminary Findings in Female Sexual Arousal Disorder

• Apricus Biosciences, Inc. (Nasdaq:APRI) (http://www.apricusbio.com) ("Apricus Bio") noted, that in a Phase III, randomized clinical trial, the female sexual arousal disorder ("FSAD") endpoint improved significantly during treatment with a topical prostaglandin compared with a placebo, MedPage Today reported on May 24. The article is available at: http://www.medpagetoday.com/MeetingCoverage/AUA/32911

  MedPage Today cited Irwin Goldstein, M.D., Director of Sexual Medicine at the Alvarado Hospital in San Diego, who reported updated findings from a Phase III, randomized, placebo-controlled clinical trial involving 387 women with FSAD (J Sex Med 2008; 5: 1923-1931). The study population included pre- and postmenopausal women in China with a mean age of 45. The study was conducted by Apricus Bio.

  The patients were randomized to a placebo or one of three concentrations of alprostadil cream, the drug contained in Apricus Bio's Femprox® (alprostadil and DDAIP.HCl for treatment of FSAD).

  MedPage Today noted that this study was published as an abstract which was presented at a conference. The data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.

  Primary source: American Urological Association

  Source reference:

  Goldstein I, et al "Updated analyses of a randomized, double-blind, phase III study of Femprox, an alprostadil cream with a novel transdermal delivery technology for the treatment of female sexual arousal disorder (FSAD)" AUA 2012; Abstract 1498.

  Source: Apricus Biosciences, Inc.